Search results for "Thrombosi"

showing 10 items of 634 documents

Differential Effects of Biologics on Psoriasis-Related Vascular Inflammation and Risk of Thrombosis

2020

Programa Estatal de I+D+i Orientada a los Retos de la Sociedad from Ministerio de Ciencia, Innovación y Universidades and European Regional Development Fund (Spain) [RTI2018-094436-B-I00]; Ministerio de Sanidad y Consumo CIBERehd (Spain) [CB06/04/0071]; Generalitat Valenciana (Spain) [PROMETEO/2018/141]; Proyectos Grupos Emergentes [GV/2019/043]; and Universidad Europea (Spain) (2018/UEM32 and 2019/UEM29]. 8.551 JCR (2020) Q1, 4/69 Dermatology 1.951 SJR (2020) Q1, 54/438 Biochemistry No data IDR 2020 UEV

Vasculitis0301 basic medicinemedicine.medical_specialtyEnfermedad cardiovascularImiquimodCell CommunicationDermatologyBiochemistryMiceTrombosis03 medical and health sciences0302 clinical medicinePsoriasis Area and Severity IndexPsoriasisProductos biológicosLeukocytesmedicineAnimalsHumansPsoriasisMolecular BiologyBody surface areaBiological ProductsImiquimodTumor Necrosis Factor-alphabusiness.industryEndothelial CellsThrombosisCell BiologyDermatology Life Quality Indexmedicine.diseaseDermatologyThrombosis030104 developmental biology030220 oncology & carcinogenesisMethotrexatebusinessEnfermedad de la pielMacemedicine.drugJournal of Investigative Dermatology
researchProduct

Transdermal Nitroglycerine Patch: An Optional Device to Reduce Flap Venous Congestion? A Case Report

2013

ABSTRACT Sometimes in free flap there is a venous congestion without an obstruction of the venous anastomosis or other organic causes of reduction venous drainage (haematoma, seroma compressing the pedicle). In these cases the authors suggest the application of nitroglycerine patch in the congested area of the flap few hours before the surgical exploration of the anastomosis. If there is a fast improvement of the clinical feature of the flap, the surgical exploration could be avoided. The authors underline that applying the nitroglycerin patch should not be regarded in any way as a therapy of a free flap venous thrombosis but only as an useful device, an option to be taken only when the sur…

Venous Congestionmedicine.medical_specialtybusiness.industryVascular Pedicle Thrombosimedicine.medical_treatmentSettore MED/19 - Chirurgia PlasticaFree flapMicrosurgical ComplicationsAnastomosismedicine.diseaseSurgeryVenous thrombosisVenous congestionAnesthesiaSeromamedicineVenous anastomosisbusinessFree Flap FailureReduction (orthopedic surgery)Transdermal
researchProduct

Superior mesenteric vein thrombosis following open right hemicolectomy and cholecystectomy. Case report

2020

INTRODUZIONE: La SMVT è una seria, rara complicanza della chirurgia addominale. I fattori di rischio sono molteplici, ma scarsamente descritti tanto che i dati sono insufficienti per creare gold standard per la diagnosi e trattamento. La SMVT ha un ampio spettro di presentazioni cliniche, così che spesso la sua diagnosi precoce può essere complessa. CASE REPORT: Una donna obesa di 56 anni con un disordine protrombotico ereditario è stata sottoposta ad emicolectomia destra e colecistectomia open; l’immediato decorso post-operatorio è stato regolare e la paziente è stata dimessa in quinta giornata post-operatoria. In ottava giornata post-operatoria la paziente ha presentato dolore addominale …

Venous ThrombosisMesenteric VeinsPostoperative ComplicationsColorectal surgery Superior mesenteric vein thrombosis Hypercoagulable disorders ThromboprophylaxisHumansthrombosiCholecystectomyFemaleMiddle Agedcholecystectomy.right hemicolectomyColectomySuperior mesenteric vein
researchProduct

Thrombotic complications of vaccination against SARS-CoV-2: what pharmacovigilance reports tell us – and what they don't

2021

In the present issue of the Journal [1], Smadja et al. present an analysis of global pharmacovigilance reports of thrombotic events following severe acute respiratory distress syndrome coronavirus (SARS-CoV)-2 vaccination. More specifically, the authors analysed the data entered into the World Health Organization (WHO) Global Database for Individual Case Safety Reports (VigiBase) between December 13, 2020 and March 16, 2021, covering, at that time, a population of almost 362 million vaccinated individuals across the world. The study focuses on three of the coronavirus disease (COVID)-19 vaccines available to date, namely the Pfizer-BioNtech (BNT162b2), Moderna (mRNA-1273), and OxfordAstraZe…

Venous ThrombosisPulmonary and Respiratory Medicine2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)SARS-CoV-2business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VaccinationCOVID-19ThrombosisVaccination03 medical and health sciencesEditorial0302 clinical medicine030228 respiratory systemPharmacovigilancemedicineHumans030212 general & internal medicineIntensive care medicinebusinessThrombotic complicationEuropean Respiratory Journal
researchProduct

Activación plaquetaria e hipercolesterolemia en la patogenia de la trombosis venosa profunda

2006

Currently it is accepted that deep vein thrombosis is a multifactorial event in which the presence of activated platelets and also plasmatic lipids seems to play a pivotal role that it is not well established in the scientific bibliography. Due to the non consensus state about these topics between the different groups working in these aspects, the topic involving deep vein thrombosis-platelets-lipids, and also their interactions, still is an interesting area of investigation, in which it is necessary to carry out studies with the aim of establishing risk factors, initial diagnostic methods and clinical assays to probe the efficacy of new therapies.

Venous thrombosisDiagnostic methodsmedicine.anatomical_structurebusiness.industryDeep veinmedicineGeneral MedicinePlatelet activationmedicine.diseaseBioinformaticsbusinessThrombosisMedicina Clínica
researchProduct

2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism

2014

ACS : acute coronary syndrome AMPLIFY : Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-line Therapy aPTT : activated partial thromboplastin time b.i.d. : bis in diem (twice daily) b.p.m. : beats per minute BNP : brain natriuretic peptide BP : blood pressure CI : confidence interval CO : cardiac output COPD : chronic obstructive pulmonary disease CPG : Committee for Practice Guidelines CRNM : clinically relevant non-major CT : computed tomographic/tomogram CTEPH : chronic thromboembolic pulmonary hypertension CUS : compression venous ultrasonography DSA : digital subtraction angiography DVT : deep vein thrombosis ELISA : enzyme-linked immunosorben…

Vitamin KVasodilator AgentsAdministration OralChest pain; Diagnosis; Dyspnoea; Guidelines; Heart failure; Hypotension; Pulmonary embolism; Shock; Thrombolysis; Treatment-Anticoagulation; Venousthrombosis; Administration Oral; Algorithms; Anticoagulants; Biomarkers; Chronic Disease; Clinical Laboratory Techniques; Diagnostic Imaging; Embolectomy; Endovascular Procedures; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Heart Failure; Home Care Services; Humans; Hypertension Pulmonary; Long-Term Care; Neoplasms; Pregnancy; Pregnancy Complications Cardiovascular; Prognosis; Pulmonary Embolism; Risk Factors; Vasoconstrictor Agents; Vasodilator Agents; Vitamin K; Cardiology and Cardiovascular MedicineEmbolectomyCardiovascularChest painPregnancyRisk FactorsNeoplasmsDiagnosisVasoconstrictor AgentsSocieties MedicalEndovascular ProceduresShockGeneral MedicinePulmonaryPrognosisThrombosisThrombolysisHome Care ServicesPulmonary embolismEuropeVenous thrombosismedicine.veinPractice Guidelines as TopicAdministrationHypertensionCardiologyApixabanFemaleRadiologyHypotensionCardiology and Cardiovascular MedicineAlgorithmsmedicine.drugOralDiagnostic Imagingmedicine.medical_specialtypumonary hypertensionmedicine.drug_classHypertension PulmonaryPregnancy Complications CardiovascularCardiologyMEDLINELow molecular weight heparin610 Medicine & healthHeart failureGuidelinesInferior vena cavaFibrin Fibrinogen Degradation ProductsText miningFibrinolytic AgentsInternal medicineDyspnoeamedicineHumansIntensive care medicinebusiness.industryClinical Laboratory TechniquesPulmonary embolismAnticoagulantsTreatment-Anticoagulationmedicine.diseasePulmonary hypertensionLong-Term CarePregnancy ComplicationsVenousthrombosisHeart failureChronic DiseasebusinessBiomarkers
researchProduct

Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban

2020

Abstract Cancer‐associated venous thromboembolism (VTE) is a frequent, potentially life‐threatening event that complicates cancer management. Anticoagulants are the cornerstone of therapy for the treatment and prevention of cancer‐associated thrombosis (CAT); factor Xa–inhibiting direct oral anticoagulants (DOACs; apixaban, edoxaban, and rivaroxaban), which have long been recommended for the treatment of VTE in patients without cancer, have been investigated in this setting. The first randomized comparisons of DOACs against low‐molecular‐weight heparin for the treatment of CAT indicated that DOACs are efficacious in this setting, with findings reflected in recent updates to published guidan…

anticoagulantsmedicine.medical_specialtyvenous thromboembolismneoplasmsReview Articlelaw.inventionchemistry.chemical_compoundRandomized controlled trialEdoxabanlawmedicinecancerIntensive care medicineReview ArticlesrivaroxabanthrombosisRivaroxabanlcsh:RC633-647.5business.industryCancerlcsh:Diseases of the blood and blood-forming organsHematologyHeparinmedicine.diseaseThrombosischemistryAmbulatoryApixabanbusinessmedicine.drugResearch and Practice in Thrombosis and Haemostasis
researchProduct

Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation -a look beyond the excellent results

2012

arterial thrombosisSettore MED/15 - Malattie Del Sangue
researchProduct

Aspirin for preventing the recurrence of venous thromboembolism

2012

aspirin venous thrombosis
researchProduct

Cellular effects of HMG-CoA reductase inhibitors on blood cells (monocytes, macrophages, platelets)

2002

Atherosclerosis is the primary cause of ischaemic heart disease (IHD) and stroke and the leading cause of death and long-term disabilities in westernized societies. Several important environmental and genetic risk factors are associated with atherosclerosis. Over the past decade, it has become evident that atherosclerosis is not simply an inevitable degenerative consequence of ageing, but rather a chronic inflammatory condition connecting altered cholesterol metabolism and other risk factors to the development and progression of the atherosclerotic lesion and its sequelae like plaque rupture, fibrosis, calcification and thrombosis [1].

biologybusiness.industrymedicine.diseaseThrombosisLesionFibrosisImmunologyHMG-CoA reductasemedicinebiology.proteinPlateletmedicine.symptombusinessStrokeCause of deathCalcification
researchProduct